Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | CA7 | P43166 | 2/20 | 0.65 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.65 |
| ▸ | PRMT1 | Q99873 | 5/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927860 | 0.82 | CA1 (0.69) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL1292933 | 0.79 | CA1 (1.00) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL27226032 | 0.79 | CA1 (0.65) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL1292932 | 0.79 | CA1 (0.65) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL1254095 | 0.79 | CA1 (0.77) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL1244815 | 0.79 | CA1 (0.65) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL17815580 | 0.78 | CA1 (0.64) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL17815582 | 0.78 | PRMT1 (0.73) | CA1CA2CA7CA13PRMT1 | |
| SCHEMBL6033642 | 0.76 | DHODH (0.56) | TRPV1CNR1EGFRFLT3TTBK1 | |
| SCHEMBL769494 | 0.76 | EGFR (0.54) | TRPV1CNR1EGFRFLT3TTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | HOLLINGWORTH GREGORY J (GB) | 2005-09-08 | — | — | US | disclosed |
| WO-2005047280-A1 | SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197342-A1 | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | OPRL1, OPRK1, CNR1 | CA1 2681/4885CA2 834/4885CA7 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.